Biomarin Pharmaceutical (BMRN) Stock
Rare disease biotech developing treatments for genetic diseases. Here's the price, business snapshot, and what's worth knowing about Biomarin Pharmaceutical in August 2026.
BioMarin Pharmaceutical Inc. (BMRN) is a clinical-stage biotechnology company specialising in treatments for rare genetic diseases. Its commercial portfolio has included enzyme-replacement and small-molecule therapies for small patient populations, while its pipeline emphasises novel approaches such as gene and enzyme therapies aimed at conditions with high unmet need. Investors should know BioMarin’s fortunes are closely tied to clinical trial readouts, regulatory decisions and pricing/reimbursement outcomes: successful approvals can materially increase revenues, but setbacks can cause sharp share-price movement. The business typically carries high R&D spend, long development timelines and single-product concentration risks common to rare-disease biotechs. With a market capitalisation of about $10.33 billion, BioMarin may appeal to investors seeking exposure to innovative therapeutics and potential upside from pipeline milestones, but it is more suitable for those with a long-term horizon and a tolerance for clinical and regulatory risk. This is general educational information, not personalised financial advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioMarin Pharmaceutical's stock, indicating strong potential for price increase.
Financial Health
Biomarin Pharmaceutical is performing well with strong profits and revenue, reflecting solid business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline-Driven Growth
Clinical readouts and approvals can create meaningful revenue shifts; however, outcomes are uncertain and can move the share price both ways.
Gene Therapy Focus
BioMarin invests in gene and enzyme therapies that could transform care for rare conditions, though development and regulatory hurdles remain significant.
Specialist Markets
Treatments target small patient populations where pricing and reimbursement matter; commercial success depends on payer acceptance and scale limitations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
